FDA Briefing Docs: Calcitonin Cancer Risk 'Appears Plausible'
Briefing documents released ahead of Tuesday's FDA advisory meeting to discuss the risk-benefit profile of calcitonin-containing drugs in osteoporosis said the cancer risk associated with the polypeptide hormone "appears plausible" and "cannot be ignored," signaling another potential blow to the drug class.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter